BioSpace News Archive

Saghmos Therapeutics, Inc., a privately held biopharmaceutical company, announced that the Japanese Patent Office has issued Japanese Patent No. 7474463 for its Phase 3-ready product, ST-62516, a cardiorenal metabolic modulator.

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2024 European Hematology Association (EHA) Congress, being held in Madrid, Spain and virtually, June 13-16, 2024.

Acclaro Medical, a medical technology company that specializes in developing and delivering trailblazing solutions for medical aesthetics and surgical practitioners worldwide, today announced clearance by the U.S. Food and Drug Administration (FDA) for a new indication of the Company’s UltraClear® cold ablative fractional 2910 nm fiber laser.

Seelos Therapeutics, Inc. announced that its Board of Directors approved a 1-for-8 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on Thursday, May 16, 2024.

REVIAN Inc., an aesthetic medical technology company using precise wavelengths of LED light to rejuvenate hair and skin, announced an upcoming presentation at the 2024 Society for Investigative Dermatology Annual Meeting being held in Dallas on May 15-18, 2024.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

The global pharmaceutical filtration market size was evaluated at US$ 12.47 billion in 2023 and is expected to attain around US$ 19.55 billion by 2033, growing at a CAGR of 4.6% from 2024 to 2033.

According to recent study by nova one advisor, the U.S. high potency active pharmaceutical ingredients market size was exhibited at USD 6.95 billion in 2023

Nyxoah Reports First Quarter 2024 Financial and Operating Results Announced DREAM U.S. pivotal study achieved primary endpoints On track for FDA approval as early as end of 2024.

Korro Bio, Inc., a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, reported financial results for the first quarter of 2024 and provided an update on its recent progress and anticipated milestones.